SCHEMBL15034097

SCHEMBL15034097

CC1(C)CN(C(=O)c2cc(Cl)ccc2F)CCN1C(=O)c1ncn(-c2cccc(Cl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MGLL Q99685 5/20 0.40
SLC6A7 Q99884 1/20 0.39
NPBWR1 P48145 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
GRM5 P41594 1/20 0.37
PDE2A O00408 2/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034174 0.94 MAPT (0.42) ALDH1A1L3MBTL1SLC6A7NPBWR1RXFP1
SCHEMBL15034081 0.91 MAPT (0.40) ALDH1A1MGLLSLC6A7SMN1; SMN2GRM5
SCHEMBL15019972 0.87 SLC6A7 (0.43) ALDH1A1MGLLSLC6A7SMN1; SMN2PKM
SCHEMBL15034089 0.87 MGLL (0.46) ALDH1A1L3MBTL1MGLLSLC6A7SMN1; SMN2
SCHEMBL15034239 0.86 SMN1; SMN2 (0.49) ALDH1A1L3MBTL1MGLLSLC6A7SMN1; SMN2
SCHEMBL15034173 0.85 MAPT (0.46) ALDH1A1SLC6A7NPBWR1RXFP1SMN1; SMN2
SCHEMBL15034094 0.84 SLC6A7 (0.42) ALDH1A1MGLLSLC6A7SMN1; SMN2KDM4E
SCHEMBL15034054 0.84 SLC6A7 (0.43) ALDH1A1MGLLSLC6A7SMN1; SMN2MAPT
SCHEMBL15020006 0.83 ALDH1A1 (0.44) ALDH1A1L3MBTL1SLC6A7SMN1; SMN2KDM4E
SCHEMBL15034076 0.83 SLC6A7 (0.39) MGLLSLC6A7GRM5POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 ALDH1A1 3952/4885L3MBTL1 3357/4885MGLL 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.